NorstellaLinQ: The Obesity Coding Gap: Identifying the Patients Claims Data Misses
Diagnosis codes capture only a fraction of the true obesity population. Measured against recorded BMI from height and weight, the majority of clinically obese patients are not identified through claims data alone, creating blind spots for patient identification, market sizing, and real-world evidence generation. In this infographic, find out: How obesity diagnosis coding is undercouting […]
The Hidden Obesity Population: Why Diagnosis Codes Fail Pharma, Payers, and Patients
More than 60% of clinically obese patients cannot be identified using diagnosis codes alone. For manufacturers, payers, and providers, that means prior authorizations fail, commercial opportunity is underestimated, and real-world evidence built on ICD-10 codes alone systematically miss eligible patients. Anti-obesity medications are the most consequential pharmacological development in obesity treatment in a generation. Semaglutide […]
How Real-World Data is Transforming GLP-1 Strategy, and the Keys to Launch Success
This webinar explores how integrated real-world data (RWD) and AI are reshaping commercial strategy for GLP-1 therapies as the obesity and cardiometabolic markets rapidly expand. Speakers discuss how combining EMR, claims, payer, and prescription data helps manufacturers identify untreated patient populations, monitor launches in near real time, understand prescribing and channel trends, and address access […]
NorstellaLinQ: Identify Obesity Treatment Opportunity Before the Market Does
For GLP-1 therapies, traditional data sources alone aren’t enough to understand the full patient journey. NorstellaLinQ’s 74 billion data points give you the full picture and help you optimize GLP-1 launch strategies in real time. This infographic shows how NorstellaLinQ: Unlocks key information on patients, providers, systems, and payers Uncovers prescribing trends for GLP-1s weeks […]
